Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action lawsuit has been filed against Iovance Biotherapeutics (IOVA) on behalf of investors who purchased securities between May 9, 2024, and May 8, 2025, alleging that Iovance made misleading statements regarding the commercial launch of Amtagvi. The lawsuit claims Iovance failed to disclose longer timelines for new Authorized Treatment Centers (ATCs) to treat patients, ineffective patient identification, and higher patient drop-offs, leading to increased costs and lower revenue. The suit was triggered by Iovance's May 8, 2025, announcement of Q1 2025 revenue of $49.3 million, down from $73.7 million in the prior quarter, and a slashed FY25 revenue guidance, causing a 44.8% stock price decline.

Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) is now subject to a securities class action lawsuit alleging misleading statements regarding the commercial launch of Amtagvi, its metastatic melanoma therapy, between May 9, 2024, and May 8, 2025. The lawsuit claims the company failed to disclose significant operational headwinds, including slower ramp-up times at new Authorized Treatment Centers (ATCs), ineffective patient identification and selection processes leading to higher patient drop-offs, and consequently, increased costs and lower-than-projected revenue. These alleged misrepresentations came to light on May 8, 2025, when Iovance reported 1Q25 product revenue of $49.3 million, a sharp decline from the prior quarter's $73.7 million, and significantly slashed its FY25 revenue guidance from $450-475 million to $250-300 million, attributing the revision to "recent launch dynamics" and ATC challenges. This disclosure precipitated a 44.8% decline in IOVA's share price to $1.75 on May 9, 2025, underscoring the market's severe reaction and the "extremely negative" sentiment surrounding these revelations.

Key Decisions for Investors

• Investors should treat Iovance Biotherapeutics with significant caution due to the pending class action lawsuit and the substantial cut in revenue guidance, which signals material issues with Amtagvi's commercial execution.
• Close monitoring of the litigation's developments and any corrective actions or further disclosures from the company regarding Authorized Treatment Center performance and patient onboarding for Amtagvi is essential.
• A thorough re-evaluation of IOVA's valuation and future prospects is advised, considering the revised outlook and potential ongoing operational challenges before making investment decisions.